JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and raises the price target from $7 to $8.
JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and raises the price target from $7 to $8.